Abstract | BACKGROUND: METHODS: The subjects were stable and untreated COPD outpatients with a percent predicted forced expiratory volume in 1 second (%FEV1) below 80%. Baseline assessments included clinical assessment, respiratory function testing, arterial blood gas analysis, the COPD assessment test (CAT™), and the Medical Outcomes Study 36-Item Short-Form Health Survey, Japanese version 2 (SF-36v2(®)). Patients underwent monitoring by uniaxial accelerometer before and after 12 weeks once-daily inhalation of indacaterol 150 μg/day. RESULTS: Eighteen patients were evaluable. Patient characteristics included a mean age of 74.2 years, and three patients were current smokers. Indacaterol improved mean (± standard deviation [SD]) %FEV1 from 55.2% (±17.9%) to 61.0% (±17.3%) (P=0.003), CAT scores from 16.4 (±10.2) points to 12.4 (±8.2) points (P=0.04), some scales of the SF-36v2 (physical component summary, 41.6±9.7 points to 45.1±7.9 points, P=0.03), and number of daily steps (3,311.5±2,103.3 steps/day to 3,841.8±2,096.8 steps/day, P=0.02), but did not affect daily energy expenditure (85.0±77.2 kcal change to 90.9±56.8 kcal, P=0.29) or exercise duration of an intensity of level 1 or more (36.4±23.9 minutes increase to 40.8±21.6 minutes, P=0.12). CONCLUSION: Twelve weeks of indacaterol improved respiratory function and quality of life, but did not significantly affect physical activity in patients with moderate-to-severe COPD.
|
Authors | Yu Nishijima, Seigo Minami, Suguru Yamamoto, Yoshitaka Ogata, Taro Koba, Shinji Futami, Kiyoshi Komuta |
Journal | International journal of chronic obstructive pulmonary disease
(Int J Chron Obstruct Pulmon Dis)
Vol. 10
Pg. 439-44
( 2015)
ISSN: 1178-2005 [Electronic] New Zealand |
PMID | 25767381
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Adrenergic beta-2 Receptor Agonists
- Bronchodilator Agents
- Indans
- Quinolones
- indacaterol
|
Topics |
- Administration, Inhalation
- Adrenergic beta-2 Receptor Agonists
(administration & dosage)
- Aged
- Aged, 80 and over
- Bronchodilator Agents
(administration & dosage)
- Drug Administration Schedule
- Exercise Tolerance
(drug effects)
- Female
- Forced Expiratory Volume
- Humans
- Indans
(administration & dosage)
- Japan
- Lung
(drug effects, physiopathology)
- Male
- Motor Activity
(drug effects)
- Pulmonary Disease, Chronic Obstructive
(diagnosis, drug therapy, physiopathology)
- Quality of Life
- Quinolones
(administration & dosage)
- Severity of Illness Index
- Time Factors
- Treatment Outcome
|